> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gillibrand Bill to Speed FDA Approval of Some Drugs
- URL: https://www.fdaweb.com/gillibrand-bill-to-speed-fda-approval-of-some-drugs/
- Published: 2023-04-27T12:00:00.000Z
- Updated: 2026-09-14T18:28:08.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154318

Rep. **Kirsten Gillibrand** (D-NY) has introduced bipartisan legislation to expedite provisional FDA approval of drugs intended to treat ALS (amyotrophic lateral sclerosis), Parkinson’s, Alzheimer’s, and other life-threatening illnesses. In a statement, Gillibrand [says](https://www.gillibrand.senate.gov/news/press/release/gillibrand-announces-legislation-to-accelerate-fda-approval-of-drugs-to-treat-life-threatening-illnesses/?type=video&ref=fdaweb.com) the standard FDA approval process takes many years to get drugs to market, and patients with rapidly progressing illnesses often don’t have many years to wait.

She says the Promising Pathway Act would accelerate the approval process by creating a “safe, accelerated approval pathway for promising drugs and make these drugs available to those who need them. Specifically, the bill would allow pharmaceutical companies to petition FDA for provisional approval of a drug that has cleared early-stage clinical trials and shown significant evidence of effectiveness. Provisional approval would make these drugs available to those whose lives depend on them while pharmaceutical companies continue to collect data and pursue full approval.”

Companion legislation is being introduced in the House, Gillibrand says.